vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $173.1M, roughly 1.6× VARONIS SYSTEMS INC). On growth, VARONIS SYSTEMS INC posted the faster year-over-year revenue change (26.9% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 15.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.
ACAD vs VRNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $173.1M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | 76.0% |
| Operating Margin | 6.1% | -1.7% |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | 26.9% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $173.1M | ||
| Q4 25 | $284.0M | $173.4M | ||
| Q3 25 | $278.6M | $161.6M | ||
| Q2 25 | $264.6M | $152.2M | ||
| Q1 25 | $244.3M | $136.4M | ||
| Q4 24 | $259.6M | $158.5M | ||
| Q3 24 | $250.4M | $148.1M | ||
| Q2 24 | $242.0M | $130.3M |
| Q1 26 | — | — | ||
| Q4 25 | $273.6M | $-27.8M | ||
| Q3 25 | $71.8M | $-29.9M | ||
| Q2 25 | $26.7M | $-35.8M | ||
| Q1 25 | $19.0M | $-35.8M | ||
| Q4 24 | $143.7M | $-13.0M | ||
| Q3 24 | $32.8M | $-18.3M | ||
| Q2 24 | $33.4M | $-23.9M |
| Q1 26 | — | 76.0% | ||
| Q4 25 | 90.8% | 78.9% | ||
| Q3 25 | 92.2% | 78.2% | ||
| Q2 25 | 92.2% | 79.5% | ||
| Q1 25 | 91.7% | 78.7% | ||
| Q4 24 | 91.6% | 83.6% | ||
| Q3 24 | 92.5% | 83.8% | ||
| Q2 24 | 92.5% | 82.8% |
| Q1 26 | — | -1.7% | ||
| Q4 25 | 6.1% | -17.5% | ||
| Q3 25 | 12.8% | -22.2% | ||
| Q2 25 | 12.2% | -24.0% | ||
| Q1 25 | 7.9% | -32.1% | ||
| Q4 24 | 59.1% | -11.1% | ||
| Q3 24 | 12.6% | -16.0% | ||
| Q2 24 | 12.6% | -22.1% |
| Q1 26 | — | — | ||
| Q4 25 | 96.3% | -16.0% | ||
| Q3 25 | 25.8% | -18.5% | ||
| Q2 25 | 10.1% | -23.5% | ||
| Q1 25 | 7.8% | -26.2% | ||
| Q4 24 | 55.4% | -8.2% | ||
| Q3 24 | 13.1% | -12.4% | ||
| Q2 24 | 13.8% | -18.4% |
| Q1 26 | — | — | ||
| Q4 25 | $1.61 | $-0.23 | ||
| Q3 25 | $0.42 | $-0.26 | ||
| Q2 25 | $0.16 | $-0.32 | ||
| Q1 25 | $0.11 | $-0.32 | ||
| Q4 24 | $0.86 | $-0.12 | ||
| Q3 24 | $0.20 | $-0.16 | ||
| Q2 24 | $0.20 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $453.5M |
| Total Assets | $1.6B | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $179.3M | ||
| Q4 25 | $177.7M | $883.7M | ||
| Q3 25 | $258.0M | $671.3M | ||
| Q2 25 | $253.6M | $770.9M | ||
| Q1 25 | $217.7M | $567.6M | ||
| Q4 24 | $319.6M | $529.0M | ||
| Q3 24 | $155.1M | $844.8M | ||
| Q2 24 | $177.1M | $582.5M |
| Q1 26 | — | $453.5M | ||
| Q4 25 | $1.2B | $598.7M | ||
| Q3 25 | $917.3M | $604.8M | ||
| Q2 25 | $822.4M | $341.5M | ||
| Q1 25 | $765.2M | $367.7M | ||
| Q4 24 | $732.8M | $455.7M | ||
| Q3 24 | $577.2M | $428.6M | ||
| Q2 24 | $516.7M | $458.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $976.9M | $1.5B | ||
| Q2 24 | $914.1M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $55.0M |
| Free Cash FlowOCF − Capex | — | $49.0M |
| FCF MarginFCF / Revenue | — | 28.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $118.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.0M | ||
| Q4 25 | $-48.7M | $24.7M | ||
| Q3 25 | $74.3M | $33.4M | ||
| Q2 25 | $64.0M | $21.3M | ||
| Q1 25 | $20.3M | $68.0M | ||
| Q4 24 | $40.4M | $24.3M | ||
| Q3 24 | $63.2M | $22.5M | ||
| Q2 24 | $25.0M | $11.7M |
| Q1 26 | — | $49.0M | ||
| Q4 25 | — | $20.7M | ||
| Q3 25 | $73.9M | $30.4M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $65.7M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | $63.2M | $21.3M | ||
| Q2 24 | — | $10.9M |
| Q1 26 | — | 28.3% | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | 26.5% | 18.8% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 48.1% | ||
| Q4 24 | — | 12.6% | ||
| Q3 24 | 25.2% | 14.4% | ||
| Q2 24 | — | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
VRNS
| SaaS | $161.1M | 93% |
| Term license subscriptions | $6.9M | 4% |
| Maintenance and services | $5.2M | 3% |
